Dexcom (NASDAQ:DXCM) mentioned on Monday its over-the-counter glucose biosensor Stelo is now available for buy in the U.S.
Stelo is designed to assist individuals, 18 years and older, with Type 2 diabetes who aren’t utilizing insulin and people with prediabetes.
The U.S. Food and Drug Administration cleared the use of the system in March, making it the first steady glucose monitor to be made available and not using a prescription.
The well being regulator had famous the product shouldn’t be utilized by individuals with problematic low blood sugar ranges, as it’s not designed to alert customers to the doubtlessly harmful situation.
The system can now be bought from Stelo.com at $99 for a single pack of two sensors, which may very well be used for as much as 30 days.
Shares of Dexcom (DXCM) gained 0.72% premarket on Monday
Source: Seekingalpha
